Biotech

Five things for pharma marketers to know: Wednesday, January 17, 2018

Five things for pharma marketers to know: Wednesday, January 17, 2018

By

Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

By

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Monday, January 8, 2018

Five things for pharma marketers to know: Monday, January 8, 2018

By

Celgene to buy Impact Biomedicines for up to $7 billion; Pfizer plans to cut 300 positions in neuroscience; Perrigo hires new CEO

Five things for pharma marketers to know: Friday, January 5, 2018

Five things for pharma marketers to know: Friday, January 5, 2018

By

Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise

Five things for pharma marketers to know: Wednesday, December 20, 2017

Five things for pharma marketers to know: Wednesday, December 20, 2017

By

Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease

Five things for pharma marketers to know: Monday, December 4, 2017

Five things for pharma marketers to know: Monday, December 4, 2017

By

CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

By

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Five things for pharma marketers to know: Tuesday, July 11, 2017

Five things for pharma marketers to know: Tuesday, July 11, 2017

By

Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

By

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Five things for pharma marketers to know: Thursday, June 15, 2017

Five things for pharma marketers to know: Thursday, June 15, 2017

By

Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Wednesday, July 29

Five things for pharma marketers to know: Wednesday, July 29

By

Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.

Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

23andMe will harness genetic research in new drug discovery unit

23andMe will harness genetic research in new drug discovery unit

By

The personal genetics company created a therapeutics group to extricate new drug targets from its research database.

Newly discovered ALS gene may lead to new drug targets

A research collaboration between medical centers, drugmaker Biogen Idec and a biotechnology institute have identified a gene that could lead to new drug targets for sporadic amyotrophic lateral sclerosis—or Lou Gehrig's disease.

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

By

The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Kyprolis data fuel Amgen oncology aspirations

Kyprolis data fuel Amgen oncology aspirations

By

Blood-cancer drug Kyprolis outperformed standard treatment in a late-stage trial testing the drug in patients with multiple myeloma, said Amgen.

Biotech Report: Ultra Man

Biotech Report: Ultra Man

By

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

J&J cancer med adds indication, lower dose

J&J cancer med adds indication, lower dose

By

The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.

What payer concerns? Sovaldi ahead of curve

What payer concerns? Sovaldi ahead of curve

By

If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.

Lemtrada US rejection snarls Sanofi

Lemtrada US rejection snarls Sanofi

By

The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.

Iclusig is back in US

Iclusig is back in US

Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

By

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Report: Dendreon looking for buyer

The prostate cancer drug company is reportedly seeking a buyer to turn things around.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

OPDP sends Warning Letter to Acorda

By

The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.